Vimarsana
Biggest News Aggregation in the World

Page 16 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® Plus LENVIMA® Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma - Vimarsana News

Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® Plus LENVIMA® Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma

Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, … Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck (NYSE: MRK), known as MSD outsi...

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program - Vimarsana News

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 American Society of … First-Time Data for KEYTRUDA ® (olaparib) ...

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® For Adults With Mild-To-Moderate Plaque Psoriasis - Vimarsana News

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® For Adults With Mild-To-Moderate Plaque Psoriasis

Amgen today announced that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Otezla ® for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act action date of December 19, 2021 . “Otezla has been prescribed to hundreds of thousands of patients with … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla ® (...

OTEZLA® Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis - Vimarsana News

OTEZLA® Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021. “Many people with mild-to-moderate plaque psoriasis still report … Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surfac...

Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab) - Vimarsana News

Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)

Published: Apr 12, 2021 TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose Regeneron Pharmaceuticals, Inc. (NASDAQ: RE...